~40% revenue growth in FY27
Management expects to sustain ~40% YoY revenue growth in FY27, driven by oncology exports and tech transfers.
SAKAR / guidance tracker
Keep management guidance in view.
Sakar Healthcare · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Oncology revenue to double to ~₹200 crore in FY27
Oncology revenue expected to double from ~₹96 crore in FY26 to ~₹200 crore in FY27, with exports becoming dominant.
EBITDA margin to sustain ~27-28% and improve
Full-year EBITDA margin of ~27-28% is sustainable and expected to improve as oncology mix increases.
Oncology facility can generate ₹800-1,000 crore at optimal utilization
The Bada oncology facility can potentially generate ₹800-1,000 crore revenue at optimal utilization over 4-5 years without significant incremental capex.